OncoSec Medical Inc (OncoSec), a subsidiary of Grand Pharmaceutical Group Ltd, is a biotechnology company that focusses on designing and developing gene therapies, therapeutics and medical approaches. It offers services to stimulate body’s immune system and attack cancer. OncoSec is conducting pipeline programs for various indications which include metastatic melanoma, triple negative breast cancer and solid tumors. The company also identifies and develops novel immune-targeting agents for use with the immunogenicity platform. It conducts pre-clinical and clinical studies targeting various cancers in collaboration with various academic medical centers and companies. OncoSec is headquartered in San Diego, California, the US.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company OncoSec Medical Inc
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Table of Contents
- OncoSec Medical Inc Company Overview
- OncoSec Medical Inc Company Snapshot
- OncoSec Medical Inc Pipeline Products and Ongoing Clinical Trials Overview
- OncoSec Medical Inc - Pipeline Analysis Overview
- OncoSec Medical Inc - Key Facts
- OncoSec Medical Inc - Major Products and Services
- OncoSec Medical Inc Pipeline Products by Development Stage
- OncoSec Medical Inc Ongoing Clinical Trials by Trial Status
- OncoSec Medical Inc Pipeline Products Overview
- Diagnostic Tool - Melanoma
- Diagnostic Tool - Melanoma Product Overview
- GenPulse Device
- GenPulse Device Product Overview
- ImmunoPulse
- ImmunoPulse Product Overview
- ImmunoPulse Clinical Trial
- NeoPulse - Head And Neck Cancer
- NeoPulse - Head And Neck Cancer Product Overview
- NeoPulse - Skin Cancer
- NeoPulse - Skin Cancer Product Overview
- Next Generation Electroporation Device
- Next Generation Electroporation Device Product Overview
- OMS-I110 - Merkel Cell Carcinoma
- OMS-I110 - Merkel Cell Carcinoma Product Overview
- OMS-I120 - Cutaneous T-Cell Lymphoma
- OMS-I120 - Cutaneous T-Cell Lymphoma Product Overview
- Visceral Lesions Applicator
- Visceral Lesions Applicator Product Overview
- OncoSec Medical Inc - Key Competitors
- OncoSec Medical Inc - Key Employees
- OncoSec Medical Inc - Locations And Subsidiaries
- Head Office
- Other Locations & Subsidiaries
- Recent Developments
- OncoSec Medical Inc, Recent Developments
- Jul 26, 2021: OncoSec to Participate in Fireside Chat at BTIG Virtual Biotechnology Conference
- Jun 24, 2021: OncoSec Appoints Brian Leuthner as Interim Chief Executive Officer
- Jun 14, 2021: OncoSec Appoints Industry Leading Electroporation Device Expert, Jeffrey Silverman, as Vice President of Product Engineering
- May 27, 2021: OncoSec to Present at the Raymond James Human Health Innovation Conference
- May 17, 2021: OncoSec Appoints Robert M. Schinagl, Ph.D. as Vice President of Program and Alliance Management
- Jun 22, 2020: OncoSec presents two late-breaking abstracts on TAVO-PLUS at the American Association for Cancer Research (AACR) Virtual Annual Meeting II
- May 27, 2020: OncoSec strengthens IP portfolio with three new patents covering TAVO and its electroporation gene delivery system
- Mar 09, 2020: OncoSec announces that the class action and related litigation brought by by Alpha Holdings have been dismissed by Nevada State Court with Prejudice
- Feb 11, 2020: OncoSec strengthens its Board of Directors with three new appointments
- Feb 03, 2020: OncoSec's visceral lesion applicator (VLA) electroporation device demonstrates targeted entry and deployment in both lung and liver in data presented at the Society of Interventional Oncology Annual Meeting
- Appendix
- Methodology
- About the Publisher
- Contact the Publisher
- Disclaimer
- OncoSec Medical Inc Pipeline Products and Ongoing Clinical Trials Overview
- OncoSec Medical Inc Pipeline Products by Equipment Type
- OncoSec Medical Inc Pipeline Products by Indication
- OncoSec Medical Inc Ongoing Clinical Trials by Trial Status
- OncoSec Medical Inc, Key Facts
- OncoSec Medical Inc, Major Products and Services
- OncoSec Medical Inc Number of Pipeline Products by Development Stage
- OncoSec Medical Inc Pipeline Products Summary by Development Stage
- OncoSec Medical Inc Ongoing Clinical Trials by Trial Status
- OncoSec Medical Inc Ongoing Clinical Trials Summary
- Diagnostic Tool - Melanoma - Product Status
- Diagnostic Tool - Melanoma - Product Description
- GenPulse Device - Product Status
- GenPulse Device - Product Description
- ImmunoPulse - Product Status
- ImmunoPulse - Product Description
- ImmunoPulse - A Phase 2 Multi-Cohort, Open-Label Study of Intratumoral Tavokinogene Telseplasmid Plus Electroporation in Combination With Pembrolizumab +/- Chemotherapy in Patients With Inoperable Locally Advanced/Metastatic Triple-Negative Breast Cancer
- NeoPulse - Head And Neck Cancer - Product Status
- NeoPulse - Head And Neck Cancer - Product Description
- NeoPulse - Skin Cancer - Product Status
- NeoPulse - Skin Cancer - Product Description
- Next Generation Electroporation Device - Product Status
- Next Generation Electroporation Device - Product Description
- OMS-I110 - Merkel Cell Carcinoma - Product Status
- OMS-I110 - Merkel Cell Carcinoma - Product Description
- OMS-I120 - Cutaneous T-Cell Lymphoma - Product Status
- OMS-I120 - Cutaneous T-Cell Lymphoma - Product Description
- Visceral Lesions Applicator - Product Status
- Visceral Lesions Applicator - Product Description
- OncoSec Medical Inc, Key Employees
- OncoSec Medical Inc, Other Locations
- Glossary
- OncoSec Medical Inc Pipeline Products by Equipment Type
- OncoSec Medical Inc Pipeline Products by Development Stage
- OncoSec Medical Inc Ongoing Clinical Trials by Trial Status
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Amgen Inc
- Biogen Inc
- Gilead Sciences Inc
- NovaBay Pharmaceuticals Inc
